Compare Moderna, Inc. (MRNA) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Palo Alto Networks Inc — how do they compare? Moderna, Inc. trades at $136.2 (market cap $54.14B), while Palo Alto Networks Inc trades at $334 (market cap $273.11B). The key difference: Palo Alto Networks Inc is far larger — about 5× Moderna, Inc.'s market cap. Which is the better fit depends on your goals.
| MRNA | PANW | |
|---|---|---|
Market Cap | $54.14B | $273.11B |
Sector | Health | Technology |
52-Week High | $174.38 | $396.00 |
52-Week Low | $22.36 | $141.67 |
Enterprise Value | $50.29B | $272.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Palo Alto Networks (PANW) trades at $336.98, up 1.12% with a bearish technical signal but strong fundamentals. Revenue grew to $9.22B in 2025, with EPS beats in recent quarters. The stock faces high valuation multiples (P/E 293.03) and mixed sentiment amid AI-driven growth and recent price volatility.
Outlook: Growth is supported by AI security demand and platformization strategy, but risks include premium valuation and competitive pressures. Analyst consensus is bullish with a $410.48 price target, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
